Why Is NEKTAR THERAPEUTICS (NKTR) Stock Down Today?

NKTR stock fell 8.78% to $60.97 in early trading on concerns related to a patent dispute with Eli Lilly and a cut in price targets from analysts. The stock opened with a small gap lower and continued to trend down through the morning session. The move reflects investor reaction to a jury currently deliberating in the lawsuit and a downgrade from Wedbush.

What Happened

Nektar Therapeutics (NKTR) dropped sharply as a jury in the patent dispute over Rezpeg with Eli Lilly entered its deliberation phase. The lawsuit has cast uncertainty over the future of the drug, which is central to Nektar’s pipeline. In addition, Wedbush lowered its price target for NKTR from $80 to $50, signaling a significant shift in expectations. The stock had already fallen 11% in prior trading, and the latest developments have accelerated the sell-off. The company remains in a quiet period through its public announcement of data from the 24-week off-treatment follow-up period of the Phase 2b REZOLVE-AA study. This period limits public commentary and may contribute to the lack of near-term clarity for investors.

What The Data Shows

The stock opened at $60.46, a modest -0.8% gap from the prior close, and continued to trade lower throughout the session. Volume remained at 0.0M shares, which is 0.0x the 3-month daily average. Nektar’s fundamentals remain weak, with a trailing twelve-month (TTM) revenue decline of 27.2% and an unprofitable EPS of -6.47. The stock is currently trading within its 52-week range of $33.40 to $109.00, having printed one of 17 fresh 52-week lows on September 22. Insiders have sold a total of $441K in shares over the last 90 days, including recent transactions by the CEO and Chief R&D Officer.

What To Watch

Investors should monitor the outcome of the Eli Lilly patent trial, which could have material implications for Nektar’s intellectual property and future product strategy. The company’s quiet period is expected to end with the public announcement of data from the REZOLVE-AA study, which may provide further insight into the potential of Rezpegaldesleukin.